The addition of monoclonal anti-CLDN18.2 antibody Zolbetuximab to chemotherapy has led to significant improvement in median OS and is now considered to be the standard-of-care option in the first-line setting for patients with CLDN18.2-positive, HER2-negative GC and GEJ tumors [43]. Here, CLDN18 is linked to gastric cancer.